How to Get Jardiance in North Dakota

What Is Jardiance and Why Do Doctors Prescribe It?

Empagliflozin is a sodium-glucose cotransporter-2 (SGLT-2) inhibitor approved by the FDA for type 2 diabetes, heart failure, and chronic kidney disease. It works by blocking glucose reabsorption in the proximal tubule of the kidney, lowering blood sugar independent of insulin secretion. The cardiovascular and renal outcome data behind the drug are among the strongest in its class.

EMPA-REG OUTCOME (N=7,020 adults with type 2 diabetes and established cardiovascular disease) showed that empagliflozin reduced the composite of cardiovascular death, non-fatal myocardial infarction, and non-fatal stroke by 14% relative to placebo (hazard ratio 0.86; 95% CI 0.74-0.99) [1]. Cardiovascular mortality fell by 38% (HR 0.62; 95% CI 0.49-0.77) [1]. Those numbers drove the FDA's 2016 cardiovascular risk-reduction label update for type 2 diabetes [2].

The EMPEROR-Reduced trial (N=3,730) demonstrated a 25% relative risk reduction in the composite of cardiovascular death or hospitalization for heart failure in patients with HFrEF regardless of diabetes status (HR 0.75; 95% CI 0.65-0.86; P<0.001) [3]. EMPEROR-Preserved (N=5,988) then confirmed benefit across the full ejection-fraction spectrum (HR 0.79; 95% CI 0.69-0.90) [4]. The EMPA-KIDNEY trial (N=6,609) extended these findings to CKD, showing a 28% reduction in kidney disease progression or cardiovascular death (HR 0.72; 95% CI 0.64-0.82; P<0.001) [5].

The American Diabetes Association's 2024 Standards of Care list empagliflozin as a preferred agent in adults with type 2 diabetes and established atherosclerotic cardiovascular disease, heart failure, or CKD, independent of A1C target [6].

Who Can Prescribe Jardiance in North Dakota?

Any licensed prescriber in North Dakota can write a Jardiance prescription. MDs and DOs have full prescribing authority. Nurse practitioners in North Dakota hold full practice authority under N.D. Cent. Code § 43-12.1, meaning they can prescribe Schedule II-V controlled substances and non-controlled medications, including empagliflozin, without a supervising physician agreement [7]. Physician assistants may prescribe under a delegation agreement with a collaborating physician per N.D. Cent. Code § 43-17 [8].

Telehealth prescribing is explicitly permitted. North Dakota's telehealth parity law (N.D. Cent. Code § 26.1-36-09.15) requires commercial insurers to cover services delivered via synchronous audio-video at parity with in-person visits [9]. A prescriber licensed in North Dakota can conduct an initial telehealth evaluation, review labs, and generate a Jardiance prescription without the patient ever entering a physical clinic.

The HealthRX clinical team uses a three-checkpoint framework before issuing any SGLT-2 inhibitor prescription in North Dakota:

1. Confirm eGFR is 20 mL/min/1.73 m² or higher (the FDA label cautions against initiating empagliflozin below this threshold for glycemic control) [2].
2. Verify no active genitourinary infections, as SGLT-2 inhibitors increase risk of mycotic genital infections by roughly 3- to 4-fold [10].
3. Screen for volume depletion, particularly in patients on loop diuretics or aged 75 or older, given the drug's osmotic diuretic effect [2].

What Labs Are Required Before Getting Jardiance in North Dakota?

Labs are non-negotiable before a prescriber will write the first Jardiance prescription. The minimum required panel includes a basic or comprehensive metabolic panel (BMP/CMP) to assess renal function, serum potassium, and glucose, plus a calculated eGFR and a spot urine albumin-to-creatinine ratio (UACR) [5][6].

The UACR matters because Jardiance dosing and monitoring intensity differ between patients with CKD-range albuminuria (UACR 30-300 mg/g or above 300 mg/g) and those with normal kidney function [5]. The ADA recommends UACR measurement at least annually in all patients with type 2 diabetes on SGLT-2 inhibitors [6].

For patients being evaluated via telehealth, most North Dakota labs will accept an electronic order from an out-of-state platform provider. LabCorp has 3 draw sites in the Bismarck metro area and 2 in Fargo. Quest Diagnostics operates locations in Grand Forks and Minot. Results typically transmit within 24-48 hours, allowing the prescriber to complete the chart review and send the prescription to the patient's preferred pharmacy in the same week.

Hemoglobin A1C is required only when the indication is type 2 diabetes. For heart failure or CKD indications, A1C is informative but not a prescribing gate [6]. A lipid panel is not required before Jardiance but is often ordered alongside it as part of a comprehensive cardiometabolic workup, consistent with AHA/ACC 2023 cardiovascular prevention guidelines [11].

How to Get a Jardiance Prescription in North Dakota Step by Step

Getting a Jardiance prescription in North Dakota follows the same basic sequence whether you see a local doctor or use a telehealth platform.

Step 1. Schedule an evaluation. Book an appointment with an ND-licensed prescriber. Telehealth platforms serving North Dakota include national services as well as regional platforms affiliated with Sanford Health and CHI St. Alexius, both of which operate telemedicine services within the state.

Step 2. Complete pre-visit labs. Order or complete BMP/CMP, eGFR, and UACR at a local draw site before the appointment so results are in hand during the visit [6].

Step 3. Attend the clinical evaluation. The prescriber will review cardiovascular and renal history, confirm no contraindications (active UTI, history of Fournier's gangrene, known hypersensitivity to empagliflozin), and discuss goals of therapy.

Step 4. Receive the electronic prescription. Jardiance is not a controlled substance, so North Dakota law permits electronic transmission to any licensed pharmacy without restriction.

Step 5. Handle insurance and prior authorization. Most commercial plans in North Dakota require prior authorization for Jardiance. PA turnaround ranges from 24 hours (urgent) to 5 business days (standard). Required documentation typically includes the diagnosis code (E11.65 for T2D with hyperglycemia, I50.x for heart failure, N18.x for CKD), recent A1C or eGFR, and a trial or documented contraindication to metformin if the indication is glycemic control.

Step 6. Pick up or receive delivery. Retail pharmacies in Bismarck, Fargo, Grand Forks, Minot, and Dickinson stock Jardiance. Mail-order pharmacies such as Express Scripts and CVS Caremark ship to all North Dakota zip codes, including rural areas with no local retail pharmacy.

Telehealth Options for Jardiance in North Dakota

Telehealth is a practical path for many North Dakota residents, particularly those in rural counties where the nearest endocrinologist or cardiologist may be 100 miles away. As of 2024, North Dakota had 1.3 primary care physicians per 1,000 residents in non-metro counties, below the national average of 1.8 [12].

Synchronous audio-video visits satisfy the prescribing standard under North Dakota law. The prescriber must hold an active North Dakota license (or hold a valid license in a compact-member state if North Dakota has joined that compact at the time of service). The Interstate Medical Licensure Compact currently includes North Dakota as a member state, meaning physicians licensed in any compact state can obtain expedited ND licensure [13].

The NP Compact similarly allows nurse practitioners licensed in compact member states to practice telehealth into North Dakota. As of July 2025, North Dakota participates in the Nurse Licensure Compact [14]. This broadens the pool of telehealth NPs who can write Jardiance prescriptions for ND patients.

After the telehealth visit, the prescriber sends the prescription electronically. Most telehealth platforms integrate with pharmacy benefit managers so that the prior authorization workflow starts immediately after the prescription is transmitted, reducing the gap between prescription and first fill.

Insurance Coverage, Prior Authorization, and Costs in North Dakota

Jardiance's list price is approximately $650-$700 per month for a 30-tablet supply at the 10 mg dose. Almost no patient pays that out of pocket.

Commercial insurance. Blue Cross Blue Shield of North Dakota, Sanford Health Plan, and most employer-sponsored plans cover Jardiance as a tier 3 specialty drug. Prior authorization is standard. The PA typically requires documentation of an FDA-approved indication plus evidence that the prescriber considered first-line agents [15]. For type 2 diabetes, most ND plans require a trial of metformin or a documented contraindication. For heart failure and CKD, clinical guidelines increasingly support direct SGLT-2 initiation, and some plans have updated their criteria to reflect the EMPEROR and EMPA-KIDNEY data [3][5].

North Dakota Medicaid. As of the publication date of this article, Jardiance is not covered on the North Dakota Medicaid preferred drug list for type 2 diabetes, heart failure, or CKD. Patients on Medicaid should discuss dapagliflozin (Farxiga), which carries similar outcome data from the DAPA-HF and DAPA-CKD trials and may have different formulary status [16].

Manufacturer savings program. Boehringer Ingelheim and Lilly offer the Jardiance Savings Card for commercially insured patients, reducing copays to as low as $10 per month. Eligibility requires commercial insurance (not Medicaid or Medicare Part D). The program is available at JardiancePro.com and processes automatically at most retail pharmacies.

Medicare Part D. Under the Inflation Reduction Act's drug pricing provisions, Medicare negotiated a maximum fair price for empagliflozin starting January 2026. In the interim, many Part D plans place Jardiance on tier 3 or 4 with a copay of $45-$100 after deductible, depending on the plan.

503A Compounding Pharmacies and Empagliflozin in North Dakota

North Dakota's Board of Pharmacy licenses 503A compounding pharmacies to prepare patient-specific medications. Empagliflozin is not a FDA-approved compounded drug category, so 503A pharmacies may compound it only for an identified individual patient with a valid prescription and a documented clinical rationale that the commercial product does not meet that patient's specific needs (for example, an allergy to an excipient in the branded tablet) [17].

503A pharmacies in North Dakota are subject to USP 795 standards for non-sterile compounding. They may ship compounded empagliflozin to the patient's address within North Dakota if the pharmacy holds an active ND license. Shipment across state lines requires compliance with both the originating and receiving state's pharmacy laws.

Compounded empagliflozin is not therapeutically equivalent to Jardiance for the purposes of insurance coverage or FDA bioequivalence standards. Patients considering compounded versions should discuss the clinical rationale with their prescriber. The FDA's guidance on compounding is explicit: compounded drugs lack the same pre-market review as approved products [17].

How Long Does It Take to Receive Jardiance in North Dakota?

Timing depends on three variables: prescriber access, prior authorization speed, and pharmacy logistics.

Telehealth appointment availability on major platforms is typically 24-72 hours for new patients. Lab turnaround at a walk-in draw site is 24-48 hours. Prior authorization adds 1-5 business days for a standard PA and 24 hours for an urgent PA when clinical criteria are met. Retail pharmacies in North Dakota fill the prescription the same day it arrives electronically if the drug is in stock. Mail-order delivery adds 3-7 business days.

A reasonable total timeline for a new patient using telehealth: labs on day 1, appointment on day 2-3, PA approval by day 5-6, and medication in hand by day 7-10. Patients with existing labs and a prior authorization on file can compress this to 2-3 days.

Monitoring After Starting Jardiance in North Dakota

Starting Jardiance is not the end of the clinical process. The prescriber should schedule a follow-up evaluation at 4-8 weeks to check renal function, given that empagliflozin causes a modest initial eGFR dip (typically 2-4 mL/min/1.73 m²) that reverses with continued use and reflects hemodynamic rather than structural kidney changes [5].

The American College of Cardiology's 2023 Expert Consensus Decision Pathway for Heart Failure recommends monitoring eGFR, serum potassium, and blood pressure at 2-4 weeks after initiating any SGLT-2 inhibitor in heart failure patients [18]. Annual UACR monitoring applies in CKD and diabetes [6].

Patients should be counseled on genital mycotic infection risk (incidence approximately 6-8% in women and 2-4% in men in clinical trials) [10], symptoms of diabetic ketoacidosis (which can occur at near-normal glucose in SGLT-2-treated patients), and the importance of holding empagliflozin 3-4 days before elective surgery per current perioperative guidelines [19].

The FDA label for Jardiance specifies: "Empagliflozin is not recommended in patients with type 1 diabetes mellitus due to the increased risk of diabetic ketoacidosis" [2]. This restriction applies regardless of prescribing channel or state.

Transferring an Existing Jardiance Prescription to North Dakota

Patients relocating to North Dakota with an active Jardiance prescription from another state can transfer it to a North Dakota pharmacy under standard pharmacy transfer rules. Because empagliflozin is not a controlled substance, no DEA-specific restrictions apply to the transfer. The receiving pharmacy contacts the original dispensing pharmacy, verifies the prescription, and processes the transfer electronically.

If the prescription was written by an out-of-state prescriber who is not licensed in North Dakota, the prescription remains valid for the number of refills authorized, but future renewals will require an ND-licensed prescriber. Patients should establish care with a North Dakota provider or an ND-licensed telehealth prescriber before refills run out.

Insurance coverage may change on relocation. Employer-sponsored plans are generally portable, but coverage tier and prior authorization requirements may differ if the plan administrator uses a different regional formulary in North Dakota.